Ray Salemme, CEO of Redpoint Bio, said: “While we are disappointed with the conclusion of our partnership with Givaudan, we believe that Redpoint’s technology platform continues to provide opportunities to discover new products for both the food and beverage and pharmaceutical industries.
“We continue to advance our taste modulation discovery programs, in addition to investigating potential therapeutic applications for our compounds for the treatment of diabetes and obesity. We recognize that due to strategic changes in focus, Givaudan was not able to continue with our collaboration. However, we continue to maintain a positive relationship with Givaudan.”